50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
CEO of biggest PE firm predicts “social unrest” (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
How You Should Be Choosing Your Stocks (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
How You Should Be Choosing Your Stocks (Ad)pixel
Kim Kardashian culls Dolce & Gabbana archives for Milan show
EXPLAINER: Italian election only part of forming government
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
CEO of biggest PE firm predicts “social unrest” (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
How You Should Be Choosing Your Stocks (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
How You Should Be Choosing Your Stocks (Ad)pixel
Kim Kardashian culls Dolce & Gabbana archives for Milan show
EXPLAINER: Italian election only part of forming government
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
CEO of biggest PE firm predicts “social unrest” (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
How You Should Be Choosing Your Stocks (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
How You Should Be Choosing Your Stocks (Ad)pixel
Kim Kardashian culls Dolce & Gabbana archives for Milan show
EXPLAINER: Italian election only part of forming government
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
CEO of biggest PE firm predicts “social unrest” (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
How You Should Be Choosing Your Stocks (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
How You Should Be Choosing Your Stocks (Ad)pixel
Kim Kardashian culls Dolce & Gabbana archives for Milan show
EXPLAINER: Italian election only part of forming government
OTCMKTS:CPHRF

Cipher Pharmaceuticals - CPHRF Stock Forecast, Price & News

$2.40
0.00 (0.00%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.33
$2.40
50-Day Range
$1.68
$2.46
52-Week Range
$1.06
$2.52
Volume
5,520 shs
Average Volume
4,681 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CPHRF stock logo

About Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Receive CPHRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPHRF Stock News Headlines

Cipher Pharmaceuticals Inc stock boosted on Friday.
Interview With Julianne Keu, Psychedelic YouTuber
See More Headlines
Receive CPHRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPHRF Company Calendar

Last Earnings
5/05/2016
Today
9/24/2022
Next Earnings (Estimated)
11/09/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CPHRF
Previous Symbol
NASDAQ:CPHR
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Craig J. Mull
    Interim CEO & Chairman
  • Dr. Diane Gajewczyk
    VP of Scientific & Medical Affairs
  • Mr. Bryan Jacobs
    Chief Financial Officer
  • David Miller
    Director of Fin.













CPHRF Stock - Frequently Asked Questions

How have CPHRF shares performed in 2022?

Cipher Pharmaceuticals' stock was trading at $1.41 on January 1st, 2022. Since then, CPHRF stock has increased by 70.2% and is now trading at $2.40.
View the best growth stocks for 2022 here
.

Are investors shorting Cipher Pharmaceuticals?

Cipher Pharmaceuticals saw a decrease in short interest in August. As of August 31st, there was short interest totaling 200 shares, a decrease of 33.3% from the August 15th total of 300 shares. Based on an average daily volume of 1,500 shares, the short-interest ratio is presently 0.1 days.
View Cipher Pharmaceuticals' Short Interest
.

When is Cipher Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CPHRF earnings forecast
.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) issued its earnings results on Thursday, May, 5th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.06. The firm had revenue of $9.10 million for the quarter, compared to analysts' expectations of $10.87 million.

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF."

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cipher Pharmaceuticals' stock price today?

One share of CPHRF stock can currently be purchased for approximately $2.40.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The official website for the company is www.cipherpharma.com. The company can be reached via phone at (905) 602-5840.

This page (OTCMKTS:CPHRF) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.